Home › Funds › DUPONT CAPITAL MANAGEMENT CORP › NAMS
DUPONT CAPITAL MANAGEMENT CORP position in NAMS
NEWAMSTERDAM PHARMA COMPANY · Health Care
DUPONT CAPITAL MANAGEMENT CORP reported holding 1 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY) in its Q3 2026 13F filing — a position valued at US$24K, representing 0.00% of its reported portfolio and ranking #35 among its reported holdings. DUPONT CAPITAL MANAGEMENT CORP has disclosed NAMS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How DUPONT CAPITAL MANAGEMENT CORP's NAMS position evolved
DUPONT CAPITAL MANAGEMENT CORP first disclosed a stake in NAMS in Q3 2023 at 1 shares (US$0K). The position peaked in Q2 2026 at 1 shares, worth US$34K. Across 13 filings, DUPONT CAPITAL MANAGEMENT CORP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 1 shares valued at US$24K.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1 | $9 | New |
| Q4 2023 | 1 | $11 | Hold |
| Q1 2024 | 1 | $24 | Hold |
| Q2 2024 | 1 | $19 | Hold |
| Q3 2024 | 1 | $17 | Hold |
| Q4 2024 | 1 | $26 | Hold |
| Q1 2025 | 1 | $20 | Hold |
| Q2 2025 | 1 | $18 | Hold |
| Q3 2025 | 1 | $28 | Hold |
| Q4 2025 | 1 | $35 | Hold |
| Q1 2026 | 1 | $32 | Hold |
| Q2 2026 | 1 | $34.00K | Hold |
| Q3 2026 | 1 | $24.00K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NAMS and 13F data
NAMS (NEWAMSTERDAM PHARMA COMPANY) is a Health Care company. 42 other funds we track also report a position in NAMS — the largest reported positions include Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$287.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NAMS
- Frazier Life Sciences Management, L.P. 18.09M sh · $613.03M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 9.55M sh · $323.66M · Q2 2026
- FCPM III SERVICES B.V. 8.49M sh · $287.74M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.26M sh · $144.53M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 3.81M sh · $129.00M · Q2 2026
- Maverick Capital 3.27M sh · $110.75M · Q2 2026
- MAVERICK CAPITAL LTD 3.27M sh · $110.75M · Q2 2026
- Duquesne Family Office LLC 3.07M sh · $104.05M · Q2 2026
- Medicxi Ventures Management (Jersey) Ltd 2.18M sh · $53.07M · Q3 2026
- Castle Hook Partners LP 1.37M sh · $46.46M · Q2 2026
- NWI MANAGEMENT LP 702.00K sh · $23.79M · Q2 2026
- Rock Springs Capital Management LP 582.74K sh · $19.75M · Q2 2026
More on DUPONT CAPITAL MANAGEMENT CORP
FAQ
How long has DUPONT CAPITAL MANAGEMENT CORP held NAMS?
DUPONT CAPITAL MANAGEMENT CORP has disclosed NAMS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is DUPONT CAPITAL MANAGEMENT CORP's current position in NAMS?
As of Q3 2026, DUPONT CAPITAL MANAGEMENT CORP holds 1 shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $24.00K, representing 0.00% of its reported portfolio and ranking #35.
Has DUPONT CAPITAL MANAGEMENT CORP been buying or selling NAMS?
In the latest 13F filing (Q3 2026), DUPONT CAPITAL MANAGEMENT CORP held unchanged its position in NAMS. The position peaked in Q2 2026 at 1 shares.
Which other funds hold NAMS?
Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.